The Washington Post partially backs claim concerning device tax impact; Israeli company launches flexible endoscope to treat acid reflux;

@FierceMedDev: FDA: Kids with diabetes can use DexCom's continuous glucose monitor. Story | Follow @FierceMedDev

@MarkHFierce: Here's my perspective, as a patient, on the pacemaker industry. Editor's corner | Follow @MarkHFierce

@MichaelGFierce: Lupin stakes a claim on the sterile injectables market. News | Follow @MichaelGFierce

@EmilyWFierce: Endo waves goodbye to HealthTronics for $130M. Report | Follow @EmilyWFierce

> The Washington Post's "The Fact Checker" blog partially backs a claim by Sen. Tim Scott (R-SC) that the 2.3% medical device tax will cost small business owners $29 billion. Blog

> Minnesota-based Sansio, a med tech patient- management software business once owned by Medtronic ($MDT), has been sold to Physio-Control. Story

> Israel's Medigus has started selling a flexible endoscope that treats acid reflux without surgery. Story

> Direct Flow Medical gained a CE mark for what it bills as the first fully repositionable 29mm transcatheter aortic heart valve. Item

> Aurora Spine in California has obtained 510(k) clearance for sterile-packed titanium plasma spray-coated spinal fusion implants. Item

Biotech News

@FierceBiotech: Eisai readies applications for thyroid cancer drug after SFJ delivers PhIII success. More | Follow @FierceBiotech

@JohnCFierce: Furiex preps for buyout talks after IBS drug looks promising in PhIII. News | Follow @JohnCFierce

@DamianFierce: Big Pharma superteam joins NIH to share data, discover new drugs. Story | Follow @DamianFierce

@EmilyMFierce: Mechanism that boosts bone growth could aid osteoporosis drug design. Article via FierceBiotech Research | Follow @EmilyMFierce

> NEA backs $14M round for a biotech startup focused on autism disorder. More

> Acucela spots a $162M Japanese IPO to get its eye drug into focus. Read

Pharma News

@FiercePharma: Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices. Story | Follow @FiercePharma

@TracyStaton: From FiercePharmaMarketing: UCB nabs Asian marketing rights to hot Biogen MS drugs. More | Follow @TracyStaton

@EricPFierce: My colleague Mark Hollmer offers a thoughtful analysis of pacemakers after having one put in. Check it out. Item | Follow @EricPFierce

@CarlyHFierce: More Humira sales gains help AbbVie meet forecasts. News | Follow @CarlyHFierce

> Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices. More

> Bayer, Roche and GSK cancer meds win nod for special U.K. funding. News

> GlaxoSmithKline's Advair loses share to AstraZeneca's aggressive Symbicort discounts. Story

Biotech Research News

> $40M gift from stem cell agency will fund new genomics initiative. Item

> Exposure to acid turns adult cells into stem cells. More

> Merck halts drug testing on chimpanzees. News

> Mechanism that boosts bone growth could aid osteoporosis drug design. Report

> Stem cell signaling protein spurs cancer spread. Story

> Epilepsy drug reverses fatty liver disease in obese mice. Article

Pharma Manufacturing News

> Daiichi Sankyo is bringing the hammer down on Ranbaxy. More

> Amgen is halting Epogen manufacturing in Colorado. Story

> Abbott is closing a plant in Puerto Rico as Mexico's Neolpharma expands. Article

> Alexion buys vial-filling facility in Ireland. News

> Lupin stakes a claim on the sterile injectables market. Report

> Sources: Recipharm looks at doing an IPO to expand cash. Item

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.